Research programme: siRNA anticancer therapeutics - Bristol-Myers Squibb/Arbutus

Drug Profile

Research programme: siRNA anticancer therapeutics - Bristol-Myers Squibb/Arbutus

Latest Information Update: 11 Sep 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Arbutus Biopharma; Bristol-Myers Squibb
  • Class Lipids; Nucleic acids; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 27 Mar 2013 Tekmira and Bristol-Myers Squibb's collaboration is ongoing in Canada
  • 27 May 2011 Early research in Cancer in Canada (Parenteral)
  • 12 May 2010 Tekmira and Bristol-Myers Squibb expand their collaboration agreement on siRNA therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top